OraSure Technologies, Inc. (NASDAQ:OSUR) – Research analysts at Jefferies Financial Group raised their FY2018 earnings per share (EPS) estimates for shares of OraSure Technologies in a note issued to investors on Tuesday, August 14th. Jefferies Financial Group analyst B. Couillard now expects that the medical instruments supplier will earn $0.33 per share for the year, up from their previous forecast of $0.31. Jefferies Financial Group also issued estimates for OraSure Technologies’ Q4 2018 earnings at $0.19 EPS.
OSUR has been the topic of several other reports. ValuEngine cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. Zacks Investment Research cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. Stephens cut shares of OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research report on Monday, July 16th. Finally, TheStreet upgraded shares of OraSure Technologies from a “c+” rating to a “b” rating in a research report on Thursday, August 9th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $21.33.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, August 8th. The medical instruments supplier reported $0.07 EPS for the quarter, topping the consensus estimate of $0.04 by $0.03. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. The firm had revenue of $43.60 million for the quarter, compared to analysts’ expectations of $42.24 million. During the same period in the previous year, the business earned $0.09 earnings per share. OraSure Technologies’s revenue for the quarter was up 8.5% compared to the same quarter last year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James & Associates boosted its stake in OraSure Technologies by 84.4% during the fourth quarter. Raymond James & Associates now owns 41,007 shares of the medical instruments supplier’s stock valued at $773,000 after buying an additional 18,771 shares during the period. MetLife Investment Advisors LLC purchased a new stake in OraSure Technologies during the fourth quarter valued at about $472,000. Rhumbline Advisers raised its position in OraSure Technologies by 2.8% during the first quarter. Rhumbline Advisers now owns 135,581 shares of the medical instruments supplier’s stock valued at $2,290,000 after purchasing an additional 3,678 shares in the last quarter. Alps Advisors Inc. raised its position in OraSure Technologies by 19.0% during the first quarter. Alps Advisors Inc. now owns 25,849 shares of the medical instruments supplier’s stock valued at $437,000 after purchasing an additional 4,129 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in OraSure Technologies during the first quarter valued at about $113,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Recommended Story: What are CEFs?
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.